Imagine a world where children with debilitating illnesses can regain their childhoods, free from the constant burden of pain and limited mobility. This is the reality being shaped by recent additions to Australia's Pharmaceutical Benefits Scheme (PBS). The PBS is expanding its reach to include crucial medications, offering a lifeline to those battling conditions like juvenile arthritis, rare liver diseases, and multiple sclerosis.
Newly listed medicines on the PBS are bringing hope and relief to many Australians. One of the key additions is Adalimumab (Humira®), which will now be available to treat juvenile idiopathic arthritis, along with other immune-mediated inflammatory diseases (IMIDs) like Crohn’s disease, ulcerative colitis, and chronic plaque psoriasis. These IMIDs can cause painful inflammation in joints, the gut, or skin, hindering growth and potentially leading to long-term disabilities. Children often find their schooling and daily activities disrupted, placing a heavy emotional, physical, and financial strain on families. Humira works by calming the immune system and reducing inflammation, enabling children to regain mobility and participate in everyday life.
Did you know that an estimated 18,500 to 30,100 Australians aged 0 to 24 are living with arthritis? Without the PBS subsidy, families could face expenses of around $650 per script. Health Minister Mark Butler emphasized the life-changing impact of these medications, highlighting that patients will now pay a maximum of $25 per script, or just $7.70 for concession card holders. This dramatic reduction underscores the PBS's commitment to providing accessible healthcare.
But here's where it gets controversial: the inclusion of these medications is a significant step, but it also raises questions about the ongoing balance between cost and access within the healthcare system. What do you think about the government's role in subsidizing expensive medications? Share your thoughts in the comments.
Other notable additions to the PBS include Odevixibat (Bylvay®) and Ublituximab (Briumvi®). Bylvay is now listed for the treatment of progressive familial intrahepatic cholestasis (PFIC), a rare genetic liver disease primarily affecting children. This disease causes a buildup of bile acids, leading to severe itching, sleep disturbances, and liver damage. It's estimated to affect between one in 50,000 and one in 100,000 live births globally. Without the PBS subsidy, families could face costs exceeding $200,000 per script.
Ublituximab (Briumvi®) is also being listed for the first time, specifically for relapsing-remitting multiple sclerosis (RRMS). RRMS is an autoimmune disease that damages the central nervous system, often causing severe symptoms and long-term disabilities. Briumvi targets the B-cells that drive inflammation, helping to reduce relapses and slow disease progression. In 2024, over 14,000 patients accessed a similar treatment through the PBS. Without the subsidy, patients might pay $15,000 per script.
The PBS operates as part of the Australian Government’s National Medicines Policy, aiming to meet medication and related service needs to achieve optimal health outcomes and economic objectives. The government subsidizes the cost of medicine for many medical conditions, with most medications dispensed by pharmacists and used at home.
And this is the part most people miss: The PBS has a rich history, beginning in 1948 as a limited scheme offering free medicines for pensioners and a list of 139 life-saving medicines free of charge for others. Today, the PBS boasts over 900 medicines listed, covering more than 5,000 different brands. The PBS Schedule lists all available medicines at a government-subsidized price, managed by the Department of Health, Disability and Ageing, and administered by Services Australia.
What are your thoughts on the PBS and its impact on healthcare accessibility? Do you think the current system is sustainable, or are there areas where it could be improved? Let's discuss in the comments below!
